391889-53-5 Usage
Uses
Used in Pharmaceutical Industry:
2-Pyrrolidinemethanol, 4-[(triphenylmethyl)thio]-, (2S,4R)is used as an intermediate in the synthesis of various pharmaceuticals. Its unique stereochemistry and functional groups make it a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
2-Pyrrolidinemethanol, 4-[(triphenylmethyl)thio]-, (2S,4R)is also utilized in the production of agrochemicals, where it can serve as a key intermediate in the synthesis of bioactive molecules with potential applications in crop protection and pest control.
Used in Organic Synthesis:
2-Pyrrolidinemethanol, 4-[(triphenylmethyl)thio]-, (2S,4R)has potential applications in the field of organic synthesis, where it can be employed as a versatile reagent or precursor for the preparation of various organic compounds with diverse structures and functionalities.
Safety Considerations:
It is important to handle 2-Pyrrolidinemethanol, 4-[(triphenylmethyl)thio]-, (2S,4R)with care, as it may possess hazardous properties. Proper safety measures should be taken during its production, storage, and use to minimize potential risks to human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 391889-53-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,1,8,8 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 391889-53:
(8*3)+(7*9)+(6*1)+(5*8)+(4*8)+(3*9)+(2*5)+(1*3)=205
205 % 10 = 5
So 391889-53-5 is a valid CAS Registry Number.
391889-53-5Relevant academic research and scientific papers
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells
Berger, Yann,Dehmlow, Henrietta,Blum-Kaelin, Denise,Kitas, Eric A.,L?ffler, Bernd-Michael,Aebi, Johannes D.,Juillerat-Jeanneret, Lucienne
, p. 483 - 498 (2007/10/03)
Endothelin-1 (ET-1) is mitogenic and/or antiapoptotic in human cancers, and antagonists to ET-1 receptors are under evaluation for cancer treatment. Inhibition of ET-1 activation by the endothelin-converting enzymes 1 a-d (ECE-1a-d; EC 3.4.24.71) represents another approach to block the ET-1 effect in cancer. To evaluate this potential, we synthesized and characterized a series of low nanomolar nonpeptidic thiol-containing ECE-1 inhibitors, and evaluated their effect, as well as the effect of inhibitors for the related metalloproteases neprilysin (NEP; EC 3.4.24.11) and angiotensin-converting enzyme (ACE; EC 3.4.15.1), on human glioblastoma cell growth. Only ECE-1 inhibitors inhibited DNA synthesis by human glioblastoma cells. Exogenous addition of ET-1 or bigET-1 to glioblastoma cells did not counterbalance the growth inhibition elicited by ECE-1 inhibitors, suggesting that ECE-1 inhibitors block the proliferation of human glioblastoma cells most likely via a mechanism not involving extracellular production of ET-1. This class of molecules may thus represent novel therapeutic agents for the potential treatment of human cancer.
